Literature DB >> 18474208

Schizophrenia and 22q11.2 deletion syndrome.

Anne S Bassett1, Eva W C Chow.   

Abstract

22q11.2 deletion syndrome (22qDS) is a genetic syndrome associated with a chromosome 22q11.2 deletion and variable phenotypic expression that commonly includes schizophrenia. Approximately 1% of patients with schizophrenia have 22qDS. The schizophrenia in 22qDS appears broadly similar to that found in the general population with respect to core signs and symptoms, treatment response, neurocognitive profile, and MRI brain anomalies. However, individuals with a 22qDS form of schizophrenia typically have distinguishable physical features, have a lower IQ, and may differ in auxiliary clinical features. IQ, length of 22q11.2 deletions, and COMT functional allele do not appear to be major risk factors for schizophrenia in 22qDS. Ascertainment biases and small sample sizes are limitations of most studies. Larger studies over the lifespan and continuing education about this underrecognized condition are needed. 22qDS-schizophrenia is an important genetic subtype and a valuable model of neurodevelopmental mechanisms involved in the pathogenesis of schizophrenia.

Entities:  

Mesh:

Year:  2008        PMID: 18474208      PMCID: PMC3129332          DOI: 10.1007/s11920-008-0026-1

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  50 in total

1.  Molecular characterization of deletion breakpoints in adults with 22q11 deletion syndrome.

Authors:  Rosanna Weksberg; Andrea C Stachon; Jeremy A Squire; Laura Moldovan; Jane Bayani; Stephen Meyn; Eva Chow; Anne S Bassett
Journal:  Hum Genet       Date:  2006-10-07       Impact factor: 4.132

2.  A complete genetic association scan of the 22q11 deletion region and functional evidence reveal an association between DGCR2 and schizophrenia.

Authors:  Sagiv Shifman; Anat Levit; Mao-Liang Chen; Chia-Hsiang Chen; Michal Bronstein; Avraham Weizman; Benjamin Yakir; Ruth Navon; Ariel Darvasi
Journal:  Hum Genet       Date:  2006-06-17       Impact factor: 4.132

Review 3.  Chromosomal abnormalities and schizophrenia.

Authors:  A S Bassett; E W Chow; R Weksberg
Journal:  Am J Med Genet       Date:  2000

4.  Differential gene expression in the hippocampus of the Df1/+ mice: a model for 22q11.2 deletion syndrome and schizophrenia.

Authors:  Sinthuja Sivagnanasundaram; Danielle Fletcher; Mike Hubank; Elizabeth Illingworth; David Skuse; Peter Scambler
Journal:  Brain Res       Date:  2007-01-10       Impact factor: 3.252

5.  Gene dosage in the developing and adult brain in a mouse model of 22q11 deletion syndrome.

Authors:  D W Meechan; T M Maynard; Y Wu; D Gopalakrishna; J A Lieberman; A-S LaMantia
Journal:  Mol Cell Neurosci       Date:  2006-11-13       Impact factor: 4.314

6.  Cognitive deficits associated with schizophrenia in velo-cardio-facial syndrome.

Authors:  Therese van Amelsvoort; Jayne Henry; Robin Morris; Michael Owen; Don Linszen; Kieran Murphy; Declan Murphy
Journal:  Schizophr Res       Date:  2004-10-01       Impact factor: 4.939

7.  In vivo response to high-resolution variation of Tbx1 mRNA dosage.

Authors:  Zhen Zhang; Antonio Baldini
Journal:  Hum Mol Genet       Date:  2007-10-04       Impact factor: 6.150

Review 8.  When half is not enough: gene expression and dosage in the 22q11 deletion syndrome.

Authors:  D W Meechan; T M Maynard; D Gopalakrishna; Y Wu; A S LaMantia
Journal:  Gene Expr       Date:  2007

9.  Analysis of TBX1 variation in patients with psychotic and affective disorders.

Authors:  Birgit H Funke; Todd Lencz; Christine T Finn; Pamela DeRosse; G David Poznik; Alex M Plocik; John Kane; John Rogus; Anil K Malhotra; Raju Kucherlapati
Journal:  Mol Med       Date:  2007 Jul-Aug       Impact factor: 6.354

10.  Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia.

Authors:  Cathryn M Lewis; Douglas F Levinson; Lesley H Wise; Lynn E DeLisi; Richard E Straub; Iiris Hovatta; Nigel M Williams; Sibylle G Schwab; Ann E Pulver; Stephen V Faraone; Linda M Brzustowicz; Charles A Kaufmann; David L Garver; Hugh M D Gurling; Eva Lindholm; Hilary Coon; Hans W Moises; William Byerley; Sarah H Shaw; Andrea Mesen; Robin Sherrington; F Anthony O'Neill; Dermot Walsh; Kenneth S Kendler; Jesper Ekelund; Tiina Paunio; Jouko Lönnqvist; Leena Peltonen; Michael C O'Donovan; Michael J Owen; Dieter B Wildenauer; Wolfgang Maier; Gerald Nestadt; Jean-Louis Blouin; Stylianos E Antonarakis; Bryan J Mowry; Jeremy M Silverman; Raymond R Crowe; C Robert Cloninger; Ming T Tsuang; Dolores Malaspina; Jill M Harkavy-Friedman; Dragan M Svrakic; Anne S Bassett; Jennifer Holcomb; Gursharan Kalsi; Andrew McQuillin; Jon Brynjolfson; Thordur Sigmundsson; Hannes Petursson; Elena Jazin; Tomas Zoëga; Tomas Helgason
Journal:  Am J Hum Genet       Date:  2003-06-11       Impact factor: 11.025

View more
  103 in total

1.  Caregiver and adult patient perspectives on the importance of a diagnosis of 22q11.2 deletion syndrome.

Authors:  G Costain; E W C Chow; P N Ray; A S Bassett
Journal:  J Intellect Disabil Res       Date:  2011-12-06

2.  Commentary: Anxiety Disorders and Perceptual Disturbances in Adolescents with 22q11.2 Deletion Syndrome Treated with SSRI: A Case Series.

Authors:  Anne S Bassett
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2011-11

Review 3.  Copy number variations in schizophrenia: critical review and new perspectives on concepts of genetics and disease.

Authors:  Anne S Bassett; Stephen W Scherer; Linda M Brzustowicz
Journal:  Am J Psychiatry       Date:  2010-05-03       Impact factor: 18.112

4.  Clinically detectable copy number variations in a Canadian catchment population of schizophrenia.

Authors:  Anne S Bassett; Gregory Costain; Wai Lun Alan Fung; Kathryn J Russell; Laura Pierce; Ronak Kapadia; Ronald F Carter; Eva W C Chow; Pamela J Forsythe
Journal:  J Psychiatr Res       Date:  2010-11       Impact factor: 4.791

Review 5.  Genetics in child and adolescent psychiatry: methodological advances and conceptual issues.

Authors:  Sarah Hohmann; Nicoletta Adamo; Benjamin B Lahey; Stephen V Faraone; Tobias Banaschewski
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-04-08       Impact factor: 4.785

6.  Genetic variants of Nogo-66 receptor with possible association to schizophrenia block myelin inhibition of axon growth.

Authors:  Stéphane Budel; Thihan Padukkavidana; Betty P Liu; Zeny Feng; Fenghua Hu; Sam Johnson; Juha Lauren; James H Park; Aaron W McGee; Ji Liao; Althea Stillman; Ji-Eun Kim; Bao-Zhu Yang; Stefano Sodi; Joel Gelernter; Hongyu Zhao; Fuki Hisama; Amy F T Arnsten; Stephen M Strittmatter
Journal:  J Neurosci       Date:  2008-12-03       Impact factor: 6.167

7.  The co-occurrence of early onset Parkinson disease and 22q11.2 deletion syndrome.

Authors:  Christina Zaleski; Anne S Bassett; Karen Tam; Andrea L Shugar; Eva W C Chow; Elizabeth McPherson
Journal:  Am J Med Genet A       Date:  2009-03       Impact factor: 2.802

8.  Premature death in adults with 22q11.2 deletion syndrome.

Authors:  A S Bassett; E W C Chow; J Husted; K A Hodgkinson; E Oechslin; L Harris; C Silversides
Journal:  J Med Genet       Date:  2009-02-25       Impact factor: 6.318

9.  Association of the PIK4CA schizophrenia-susceptibility gene in adults with the 22q11.2 deletion syndrome.

Authors:  Jacob A S Vorstman; Eva W Chow; Roel A Ophoff; Herman van Engeland; Frits A Beemer; René S Kahn; Richard J Sinke; Anne S Bassett
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2009-04-05       Impact factor: 3.568

10.  Investigation of the involvement of MIR185 and its target genes in the development of schizophrenia.

Authors:  Andreas J Forstner; F B Basmanav; Manuel Mattheisen; Anne C Böhmer; Mads V Hollegaard; Esther Janson; Eric Strengman; Lutz Priebe; Franziska Degenhardt; Per Hoffmann; Stefan Herms; Wolfgang Maier; Rainald Mössner; Dan Rujescu; Roel A Ophoff; Susanne Moebus; Preben B Mortensen; Anders D Børglum; David M Hougaard; Josef Frank; Stephanie H Witt; Marcella Rietschel; Andreas Zimmer; Markus M Nöthen; Xavier Miró; Sven Cichon
Journal:  J Psychiatry Neurosci       Date:  2014-11       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.